Celldex Therapeutics, Inc. financial data

Symbol
CLDX on Nasdaq
Industry
In Vitro & In Vivo Diagnostic Substances
Location
53 Frontage Road, Suite 220, Hampton, New Jersey
State of incorporation
Delaware
Fiscal year end
December 31
Former names
AVANT IMMUNOTHERAPEUTICS INC (to 9/29/2008), T CELL SCIENCES INC (to 8/21/1998)
Latest financial report
Q1 2024 - May 6, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.76K % +7.7%
Debt-to-equity 6.81 % -17%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 65.9M shares +39.5%
Common Stock, Shares, Outstanding 65.9M shares +39.5%
Entity Public Float 1.6B USD +23.1%
Common Stock, Value, Issued 66K USD +40.4%
Weighted Average Number of Shares Outstanding, Basic 58.9K shares +24.7%
Weighted Average Number of Shares Outstanding, Diluted 58.9K shares +24.7%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 6.07M USD +92.8%
Research and Development Expense 123M USD +33.6%
General and Administrative Expense 33.4M USD +24%
Costs and Expenses 169M USD +32.3%
Operating Income (Loss) -163M USD -30.7%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -141M USD -25.9%
Earnings Per Share, Basic -2.86 USD/shares -13%
Earnings Per Share, Diluted -2.86 USD/shares -13%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 115M USD +113%
Marketable Securities, Current 709M USD +216%
Assets, Current 835M USD +188%
Property, Plant and Equipment, Net 4.06M USD +1.65%
Operating Lease, Right-of-Use Asset 2.17M USD -40.4%
Intangible Assets, Net (Excluding Goodwill) 27.2M USD 0%
Other Assets, Noncurrent 107K USD +2.89%
Assets 869M USD +168%
Accounts Payable, Current 3.23M USD -4.15%
Employee-related Liabilities, Current 9.35M USD +24.2%
Accrued Liabilities, Current 17.5M USD +87.1%
Liabilities, Current 26.3M USD +72.8%
Operating Lease, Liability, Noncurrent 470K USD -78.2%
Other Liabilities, Noncurrent 3.47M USD -21.1%
Liabilities 30.2M USD +38.8%
Accumulated Other Comprehensive Income (Loss), Net of Tax 2.24M USD +5.7%
Retained Earnings (Accumulated Deficit) -1.43B USD -11.3%
Stockholders' Equity Attributable to Parent 839M USD +177%
Liabilities and Equity 869M USD +168%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -40.6M USD -42.2%
Net Cash Provided by (Used in) Financing Activities 436M USD +62740%
Net Cash Provided by (Used in) Investing Activities -315M USD -700%
Common Stock, Shares Authorized 297M shares 0%
Common Stock, Shares, Issued 65.9M shares +39.5%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 80.3M USD +225%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 115M USD +113%
Deferred Tax Assets, Valuation Allowance 347M USD +11.1%
Deferred Tax Assets, Gross 353M USD +10.9%
Operating Lease, Liability 2.54M USD -37%
Payments to Acquire Property, Plant, and Equipment 344K USD -41.2%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -145M USD -24.1%
Lessee, Operating Lease, Liability, to be Paid 2.74M USD -39.8%
Property, Plant and Equipment, Gross 26.4M USD +4.23%
Operating Lease, Liability, Current 1.64M USD +10.1%
Lessee, Operating Lease, Liability, to be Paid, Year Two 949K USD -49.4%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.79M USD +0.68%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 195K USD -62.1%
Lessee, Operating Lease, Liability, to be Paid, Year Three 896K USD +1127%
Deferred Tax Assets, Operating Loss Carryforwards 198M USD +4.97%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 3M shares 0%
Operating Lease, Payments 2M USD +5.26%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 775K USD +6.75%
Share-based Payment Arrangement, Expense 26.8M USD +59.3%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%